The contribution of bile acids lowering to the anti-fibrotic action is another topic of interest and therefore the effect of FGFR4-selective FGF19 analogues on NASH outcome in mice will be of great interest. Here, FGFR4 is linked to metabolic dysfunction-associated steatohepatitis.